Education
About Us
Working with TipRanks
Follow Us
Corbus Pharmaceuticals (CRBP)
NASDAQ:CRBP
Total Valuation
Corbus Pharmaceuticals has a market cap or net worth of $170.80M. The enterprise value is $87.03M.
Market Cap$170.80M
Enterprise Value$87.03M
Share Statistics
Corbus Pharmaceuticals has 17,736,464 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding17,736,464
Owned by Insiders16.12%
Owned by Institutions9.40%
Financial Efficiency
Corbus Pharmaceuticals’s return on equity (ROE) is -0.53 and return on invested capital (ROIC) is -57.20%.
Return on Equity (ROE)-0.53
Return on Assets (ROA)-0.47
Return on Invested Capital (ROIC)-57.20%
Return on Capital Employed (ROCE)-0.58
Revenue Per Employee0.00
Profits Per Employee-2.80M
Employee Count28
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Corbus Pharmaceuticals is ―. Corbus Pharmaceuticals’s PEG ratio is -0.02.
PE Ratio―
PS Ratio0.00
PB Ratio0.73
Price to Fair Value0.73
Price to FCF-1.68
Price to Operating Cash Flow-1.99
PEG Ratio-0.02
Income Statement
In the last 12 months, Corbus Pharmaceuticals had revenue of 0.00 and earned -78.54M in profits. Earnings per share was -5.90.
Revenue0.00
Gross Profit-233.00K
Operating Income-85.31M
Pretax Income-78.54M
Net Income-78.54M
EBITDA-85.08M
Earnings Per Share (EPS)-5.90
Cash Flow
In the last 12 months, operating cash flow was -64.49M and capital expenditures -7.00K, giving a free cash flow of -64.50M billion.
Operating Cash Flow-64.49M
Free Cash Flow-64.50M
Free Cash Flow per Share-3.64
Dividends & Yields
Corbus Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.46
52-Week Price Change59.70%
50-Day Moving Average8.36
200-Day Moving Average10.00
Relative Strength Index (RSI)60.59
Average Volume (3m)503.64K
Important Dates
Corbus Pharmaceuticals upcoming earnings date is May 12, 2026, TBA (Confirmed).
Last Earnings DateMar 9, 2026
Next Earnings DateMay 12, 2026
Ex-Dividend Date―
Financial Position
Corbus Pharmaceuticals as a current ratio of 8.07, with Debt / Equity ratio of 1.11%
Current Ratio8.07
Quick Ratio8.07
Debt to Market Cap0.02
Net Debt to EBITDA0.32
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Corbus Pharmaceuticals has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Corbus Pharmaceuticals EV to EBITDA ratio is -0.96, with an EV/FCF ratio of -1.26.
EV to Sales0.00
EV to EBITDA-0.96
EV to Free Cash Flow-1.26
EV to Operating Cash Flow-1.26
Balance Sheet
Corbus Pharmaceuticals has $28.49M in cash and marketable securities with $1.63M in debt, giving a net cash position of $26.86M billion.
Cash & Marketable Securities$28.49M
Total Debt$1.63M
Net Cash$26.86M
Net Cash Per Share$1.51
Tangible Book Value Per Share$11.08
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Corbus Pharmaceuticals is $41.27, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$41.27
Price Target Upside328.56% Upside
Analyst ConsensusStrong Buy
Analyst Count7
Revenue Growth Forecast―
EPS Growth Forecast-17.43%